Shares of TherapeuticsMD Inc (NASDAQ:TXMD) were up 7.9% during mid-day trading on Monday . The stock traded as high as $3.72 and last traded at $3.69, approximately 3,542,254 shares traded hands during mid-day trading. An increase of 11% from the average daily volume of 3,179,627 shares. The stock had previously closed at $3.42.

Several equities analysts recently issued reports on TXMD shares. Oppenheimer set a $9.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a report on Thursday, August 22nd. BidaskClub upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Wednesday, September 11th. ValuEngine upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of TherapeuticsMD in a report on Wednesday, August 7th. Finally, Noble Financial restated a “buy” rating and issued a $13.00 target price on shares of TherapeuticsMD in a report on Monday, August 12th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $9.16.

The company has a quick ratio of 4.99, a current ratio of 5.17 and a debt-to-equity ratio of 24.29. The stock has a market capitalization of $808.09 million, a P/E ratio of -6.25 and a beta of 1.70. The firm’s 50 day simple moving average is $2.75 and its two-hundred day simple moving average is $3.53.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 212.57%. The company had revenue of $6.08 million during the quarter, compared to the consensus estimate of $5.12 million. During the same period last year, the firm posted ($0.15) earnings per share. The company’s revenue for the quarter was up 60.0% on a year-over-year basis. As a group, equities research analysts expect that TherapeuticsMD Inc will post -0.73 earnings per share for the current year.

In related news, CEO Robert G. Finizio purchased 52,405 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was purchased at an average cost of $2.96 per share, with a total value of $155,118.80. Following the completion of the purchase, the chief executive officer now owns 18,166,559 shares in the company, valued at approximately $53,773,014.64. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert G. Finizio purchased 35,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was bought at an average cost of $2.74 per share, with a total value of $95,900.00. Following the completion of the purchase, the chief executive officer now owns 18,253,964 shares of the company’s stock, valued at approximately $50,015,861.36. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 170,549 shares of company stock valued at $493,167. Insiders own 18.91% of the company’s stock.

Several large investors have recently bought and sold shares of TXMD. Frontier Capital Management Co. LLC increased its position in shares of TherapeuticsMD by 291.5% during the first quarter. Frontier Capital Management Co. LLC now owns 5,857,096 shares of the company’s stock worth $28,524,000 after acquiring an additional 4,360,963 shares in the last quarter. Rubric Capital Management LP increased its position in shares of TherapeuticsMD by 203.6% during the first quarter. Rubric Capital Management LP now owns 4,690,970 shares of the company’s stock worth $22,845,000 after acquiring an additional 3,145,742 shares in the last quarter. SG Americas Securities LLC increased its position in shares of TherapeuticsMD by 470.5% during the second quarter. SG Americas Securities LLC now owns 2,804,571 shares of the company’s stock worth $7,292,000 after acquiring an additional 2,312,933 shares in the last quarter. C WorldWide Group Holding A S increased its position in shares of TherapeuticsMD by 222.3% during the second quarter. C WorldWide Group Holding A S now owns 3,189,834 shares of the company’s stock worth $8,294,000 after acquiring an additional 2,200,000 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of TherapeuticsMD by 3,177.6% during the second quarter. Invesco Ltd. now owns 2,155,247 shares of the company’s stock worth $5,603,000 after acquiring an additional 2,089,491 shares in the last quarter. 77.99% of the stock is owned by institutional investors.

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Featured Article: Derivative

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.